Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness

被引:33
|
作者
Foos, G [1 ]
Hauser, CA [1 ]
机构
[1] La Jolla Canc Res Ctr, Burnham Inst, La Jolla, CA 92037 USA
关键词
prostate cancer; Ets2; overexpression; dominant negative Ets2; transformation;
D O I
10.1038/sj.onc.1203946
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The Ets family of transcription factors are important downstream targets in cellular transformation, as altering Ets activity has been found to reverse the transformed phenotype of Ras transformed mouse fibroblasts and of several human tumor cell lines. To determine whether Ets factors are important targets in the largely uncharacterized aberrant signaling in prostate cancer, we have altered Ets activity in the prostate tumor cell line PPC-1, by stable expression of either full-length Ets2, or a dominant inhibitor of Ets activity, the Ets2 DNA binding domain (Ets2DBD). Analysis of multiple independent clonal cell lines revealed that expression of either Ets2 or the Ets2DBD inhibited the anchorage-independent growth of PPC-1 cells up to 20-fold. In contrast to our previous findings with Ras-transformed NIH3T3 cells, PPC-1 cell lines expressing either Ets2 or the EtsDBD exhibited slower attached cell growth, increased Ets-dependent gene expression, and up to a 10-fold increase in apoptotic cell death. The p21(cip) gene was identified as a potential target of altered Ets signaling. Interestingly, the two distinct Ets2 constructs had strikingly different effects on in vitro invasiveness. Expression of the Ets2DBD almost completely blocked PPC-1 cell invasion through Matrigel, whereas overexpression of full-length Ets2 did not inhibit invasion. Overall, these results demonstrate that the balance of Ets factor activity can regulate multiple aspects of the transformed phenotype of PPC-1 prostate tumor cells, including anchorage-independent growth, survival, and invasiveness.
引用
收藏
页码:5507 / 5516
页数:10
相关论文
共 50 条
  • [1] Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness
    Gabriele Foos
    Craig A Hauser
    Oncogene, 2000, 19 : 5507 - 5516
  • [2] Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells
    Zagon, IS
    McLaughlin, PJ
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2004, 24 (06) : 1443 - 1448
  • [3] ANCHORAGE-INDEPENDENT GROWTH-CONFERRING FACTOR PRODUCTION BY RAT MAMMARY-TUMOR CELLS
    ZWIEBEL, JA
    DAVIS, MR
    KOHN, E
    SALOMON, DS
    KIDWELL, WR
    CANCER RESEARCH, 1982, 42 (12) : 5117 - 5125
  • [4] Anchorage-independent growth of human cancer cells is inhibited by opioid growth factor
    Zagon, IS
    McLaughlin, PJ
    FASEB JOURNAL, 2004, 18 (05): : A1200 - A1200
  • [5] Imperatorin sensitizes anoikis and inhibits anchorage-independent growth of lung cancer cells
    Kanuengnit Choochuay
    Preedakorn Chunhacha
    Varisa Pongrakhananon
    Rataya Luechapudiporn
    Pithi Chanvorachote
    Journal of Natural Medicines, 2013, 67 : 599 - 606
  • [6] Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells
    Fiucci, G
    Ravid, D
    Reich, R
    Liscovitch, M
    ONCOGENE, 2002, 21 (15) : 2365 - 2375
  • [7] Imperatorin sensitizes anoikis and inhibits anchorage-independent growth of lung cancer cells
    Choochuay, Kanuengnit
    Chunhacha, Preedakorn
    Pongrakhananon, Varisa
    Luechapudiporn, Rataya
    Chanvorachote, Pithi
    JOURNAL OF NATURAL MEDICINES, 2013, 67 (03) : 599 - 606
  • [8] Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells
    Giusy Fiucci
    Dana Ravid
    Reuven Reich
    Mordechai Liscovitch
    Oncogene, 2002, 21 : 2365 - 2375
  • [10] Trametinib preferentially suppresses anchorage-independent growth in osteosarcoma cells and exerts anti-tumor activity
    Shimizu, Takatsune
    Kimura, Kiyomi
    Sugihara, Eiji
    Yamaguchi, Sayaka
    Nobusue, Hiroyuki
    Muto, Akihiro
    Saya, Hideyuki
    CANCER SCIENCE, 2021, 112 : 460 - 460